证券代码：000950 证券简称：重药控股 公告编号：2025-058 重药控股股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）分别于 2025 年 7 月 10 日、2025 年 7 月 28 日召开第九届董事会第十五次会议、2025 年第三次临时股东会，审议 通过了《关于回购公司股份的议案》，同意公司使用自有资金及股票回购专项贷 款，通过深圳证券交易所交易系统以集中竞价交易方式回购公司已发行的人民币 普通股（A 股），用于减少公司注册资本。本次用于回购股份的资金总额不低于 人民币 8,000 万元（含本数），不超过人民币 10,000 万元（含本数），回购价格 不超过人民币 6.6 元/股（含本数），回购期限为自股东会审议通过回购股份事项 之日起 12 个月内。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露 的相关公告。 1.公司未在下列期间回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

Group 1 - The pharmaceutical industry is experiencing a surge in mergers and acquisitions (M&A) in the first quarter of this year [1] - State-owned enterprises (SOEs) in the pharmaceutical sector are accelerating their M&A activities, with notable actions from China National Pharmaceutical Group, China General Technology Group, and China Resources Group [2] - Private leading pharmaceutical companies are also speeding up acquisitions and innovating their business layouts, such as Mindray Medical's planned acquisition of Huatai Medical for 6.65 billion yuan [2] - Multinational pharmaceutical companies are acquiring Chinese biotech firms, exemplified by AstraZeneca's acquisition of Gensight Biologics, marking the first complete acquisition of a Chinese biotech company by a multinational [2] Group 2 - Favorable policies for M&A have been introduced, including support for SOE restructuring and optimization of asset evaluation management by the State-owned Assets Supervision and Administration Commission [3] - The China Securities Regulatory Commission is promoting market-oriented reforms in the M&A sector, which is expected to enhance the vitality of listed companies' M&A activities [3] - The industry is witnessing a valuation correction after a period of capital overheating, with some innovative pharmaceutical companies facing financial pressure, making M&A a viable option for capital infusion [3] Group 3 - Current market conditions impose stricter standards for M&A targets, favoring companies with mature product systems and stable profitability, as well as those with differentiated product pipelines and strong R&D capabilities [4] - Companies are advised to focus on resource optimization and industry synergy during M&A, conducting thorough research on target asset quality to enhance transaction quality and avoid blind acquisitions [4]

证券代码：000950 证券简称：重药控股 公告编号：2025-057 重药控股股份有限公司 关于控股子公司2025年度第一期超短期融资券 发行结果公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本年度，在《接受注册通知书》（中市协注〔2023〕SCP505号）项下，重庆 医药（集团）股份有限公司累计已发行一期超短期融资券（含本期），累计发行 金额7亿元。本期发行后，重庆医药（集团）股份有限公司超短期融资券余额7亿 元，剩余额度43亿元。 特此公告 重药控股股份有限公司董事会 | 名称 | | 简称 | 25渝医药SCP001 | | --- | --- | --- | --- | | 代码 | 012581862 | 期限 | 145天 | | 起息日 | 2025年8月7日 | 兑付日 | 2025年12月30日 | | 计划发行总额 | 不超过7亿元 | | 实际发行总额 7亿元 | | 发行利率 | 1.77% | 发行价格 | 100元/百元面值 | | | 中国民生银行股份有限公司 | | | 主承销商 中国银行股份有限公司 本 次 超 短 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-057 重药控股股份有限公司 关于控股子公司2025年度第一期超短期融资券 发行结果公告 重庆医药（集团）股份有限公司2025年度第一期超短期融资券于2025年8月 6日完成发行，募集资金已于2025年8月7日到账。现将发行结果公告如下： | 名称 | 重庆医药（集团）股份有限公司 2025年度第一期超短期融资券 | 简称 | 25渝医药SCP001 | | --- | --- | --- | --- | | 代码 | 012581862 | 期限 | 145天 | | 起息日 | 2025年8月7日 | 兑付日 | 2025年12月30日 | | 计划发行总额 | 不超过7亿元 | 实际发行总额 | 7亿元 | | 发行利率 | 1.77% | 发行价格 | 100元/百元面值 | | 主承销商 | 中国民生银行股份有限公司 | | | | | 中国银行股份有限公司 | | | 本 次 超 短 期 融 资 券 发 行 情 况 的 有 关 文 件 在 中 国 货 币 网 （www.chinamoney.com.cn）和上海清算所（www.shcl ...

Group 1 - The company, Chongqing Pharmaceutical Holdings (000950), confirmed on August 6 that its retail pharmacies sell various mosquito repellent products and analgesics [1]

证券代码：000950 证券简称：重药控股 公告编号：2025-056 重药控股股份有限公司 关于回购股份用于注销并减少注册资本暨 通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、通知债权人原因 由于本次回购的股份将依法全部予以注销并减少公司注册资本，根据《中华 人民共和国公司法》等相关法律、法规的规定，公司债权人自本公告披露之日起 45 日内，有权凭有效债权证明文件及相关凭证要求公司清偿债务或者提供相应 担保。债权人如逾期未向公司申报债权，不会因此影响其债权的有效性，相关债 务（义务）将由公司根据原债权文件的约定继续履行。 债权申报所需材料：公司债权人可持证明债权债务关系存在的合同、协议及 其他凭证的原件及复印件到公司申报债权。债权人为法人的，需同时携带法人营 业执照副本原件及复印件、法定代表人身份证明文件；委托他人申报的，除上述 文件外，还需携带法定代表人授权委托书和代理人有效身份证件的原件及复印件。 债权人为自然人的，需同时携带有效身份证件的原件及复印件；委托他人申报的， 除前述文件外，还需携带授权委托书和代理人有效身份证件的原件及 ...

Core Viewpoint - The company, Chongqing Pharmaceutical Holdings (重药控股), has indicated through its investor interaction platform that its retail pharmacies are selling various mosquito repellent products and analgesics [1] Company Summary - Chongqing Pharmaceutical Holdings operates retail pharmacies that offer a range of products, including mosquito repellent and pain relief medications [1]

Core Viewpoint - The company has approved a share repurchase plan using its own funds and a special loan, with a total amount between RMB 80 million and RMB 100 million, and a maximum repurchase price of RMB 6.6 per share [1][2]. Group 1 - The company held its ninth board meeting and third extraordinary shareholders' meeting on July 10 and July 28, 2025, respectively, to discuss the share repurchase proposal [1]. - The repurchase will be conducted through the Shenzhen Stock Exchange trading system within 12 months from the approval date [1]. - As of July 31, 2025, the company has not yet implemented the share repurchase [1]. Group 2 - The company plans to execute the share repurchase based on market conditions and will fulfill its information disclosure obligations as required [2].